News & Media
Continuing the conversation around our cause.
Keep up to date with the latest developments from Neuroene Therapeutics, our team, and partners.
Be sure to check back often for the latest news from our laboratory and around the industry.
Announcements
Neuroene pitched at BIO Startup Stadium 2024!
Posted Jun 5, 2024
Neuroene is a J&J / BARDA Blue Knight QuickFire Challenge Winner!
Posted Jun 2, 2024
Neuroene will be presenting at the Blue Knight Symposium
Posted Jun 2, 2023
Neuroene is a Finalist for BIO Startup Stadium
Posted Jun 1, 2023
Neuroene Therapeutics Receives NIH SBIR Award for Novel Antiseizure Drug with Potential for Public Health Emergency Response
Posted May 18, 2023
Neuroene Therapeutics is a resident company of Johnson & Johnson Innovation
Posted Jul 20, 2022
FDA Grants Orphan Drug Designation for Neuroene Therapeutics Drug NT102 for Dravet Syndrome
Posted Oct 12, 2021
Neuroene Therapeutics will be at the NIH Commercialization Training Workshop in Los Angeles
Posted Oct 24, 2019
Neuroene Therapeutics will be at the NHLBI Innovation Conference and Life Sciences Summit in New York City
Posted Sep 5, 2019
Neuroene Therapeutics will be at BIO 2019 in Philadelphia
Posted Jun 3, 2019
Neuroene Therapeutics Selected by CED to Present at CED Life Science Conference in Raleigh
Posted Jan 22, 2019
Neuroene Therapeutics Awarded $1.5 Million to Develop Anti-Seizure Compound for Epilepsy
Posted Oct 31, 2018
Neuroene Therapeutics Selected as Early-Stage Presenting Company at SEBIO Investor Forum in Atlanta
Posted Oct 11, 2018
Neuroene Therapeutics Awarded NIH Phase II SBIR
Posted Aug 18, 2018
SCRA/FRD Pilot Grant Awarded for Parkinson’s Disease Study
Posted Jun 25, 2018
Neuroene Therapeutics Invited to Pitch at NISBRE in Washington, D.C.
Posted Jun 23, 2018
Patent Issued: Compositions and Methods for Treating Neurological Diseases or Injury
Posted Jan 9, 2018